Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial - 01/03/22
, Quchang Ouyang, MD b, Tao Sun, MD c, Limin Niu, MD a, Jin Yang, MD d, Li Li, MD e, Yuhua Song, MD f, Chunfang Hao, MD g, Zhanhong Chen, MM h, Armando Orlandi, MD i, Naohiro Ishii, MD k, Kazuaki Takabe, MD l, Gianluca Franceschini, MD j, Francesco Ricci, MD m, Claire Verschraegen, MD n, Zhenzhen Liu, MD a, Mengwei Zhang, MM a, Huimin Lv, MM a, Liping Liu, MB b, Xiaohong Yang, MB b, Huawu Xiao, MM b, Zhichao Gao, MM c, Xiaorui Li, MM c, Fangyuan Dong, MM c, Xiuchun Chen, MM a, Jianghua Qiao, MD a, Guifang Zhang, MB oSummary |
Background |
Patients with HER2-positive metastatic breast cancer have a high risk of developing brain metastases. Efficacious treatment options are scarce. We investigated the activity and safety of pyrotinib plus capecitabine in patients with HER2-positive metastatic breast cancer and brain metastases.
Methods |
We did a multicentre, single-arm, two-cohort, phase 2 trial in eight tertiary hospitals in China. Patients aged 18 years or older who had radiotherapy-naive HER2-positive brain metastases (cohort A) or progressive disease after radiotherapy (cohort B), with an Eastern Cooperative Oncology Group performance status of 0–2, received pyrotinib 400 mg orally once daily, and capecitabine 1000 mg/m2 orally twice daily for 14 days, followed by 7 days off every 3 weeks until disease progression or unacceptable toxicity. The primary endpoint was confirmed intracranial objective response rate by investigator assessment according to the Response Evaluation Criteria In Solid Tumours (version 1.1). Activity and safety were analysed in patients with at least one dose of study drug. The study is ongoing, but recruitment is complete. The study is registered with ClinicalTrials.gov, NCT03691051.
Findings |
Between Jan 29, 2019, and July 10, 2020, we enrolled 78 women: 51 (86%) of 59 patients in cohort A and 18 (95%) of 19 patients in cohort B had previous exposure to trastuzumab. Median follow-up duration was 15·7 months (IQR 9·7–19·0). The intracranial objective response rate was 74·6% (95% CI 61·6–85·0; 44 of 59 patients) in cohort A and 42·1% (20·3–66·5; eight of 19 patients) in cohort B. The most common grade 3 or worse treatment-emergent adverse event was diarrhoea (14 [24%] in cohort A and four [21%] in cohort B). Two (3%) patients in cohort A and three (16%) in cohort B had treatment-related serious adverse events. No treatment-related deaths occurred.
Interpretation |
To our knowledge, this is the first prospective study showing the activity and safety of pyrotinib plus capecitabine in patients with HER2-positive breast cancer and brain metastases, especially in radiotherapy-naive population. This combination deserves further validation in a randomised, controlled trial.
Funding |
National Cancer Centre Climbing Foundation Key Project of China, Jiangsu Hengrui Pharmaceuticals.
Translation |
For the Chinese translation of the abstract see Supplementary Materials section.
Le texte complet de cet article est disponible en PDF.Plan
Vol 23 - N° 3
P. 353-361 - mars 2022 Retour au numéro
Article précédent
- Genetic predisposition to cancer across people of different ancestries in Qatar: a population-based, cohort study
- Mohamad Saad, Younes Mokrab, Najeeb Halabi, Jingxuan Shan, Rozaimi Razali, Khalid Kunji, Najeeb Syed, Ramzi Temanni, Murugan Subramanian, Michele Ceccarelli, Qatar Genome Programme Research Consortium, Arash Rafii Tabrizi, Davide Bedognetti, Lotfi Chouchane, Said I Ismail, Wadha Al-Muftah, Radja Badji, Hamdi Mbarek, Dima Darwish, Tasnim Fadl, Heba Yasin, Maryem Ennaifar, Rania Abdellatif, Fatima Alkuwari, Muhammad Alvi, Yasser Al-Sarraj, Chadi Saad, Eleni Fethnou, Fatima Qafoud, Eiman Alkhayat, Nahla Afifi, Sara Tomei, Wei Liu, Stephan Lorenz, Najeeb Syed, Hakeem Almabrazi, Fazulur R Vempalli, Ramzi Temanni, Tariq Abu Saqri, Mohammedhusen Khatib, Mehshad Hamza, Tariq Abu Zaid, Ahmed El Khouly, Tushar Pathare, Shafeeq Poolat, Rashid Al-Ali, Omar Albagha, Souhaila Al-Khodor, Mashael Alshafai, Ramin Badii, Lotfi Chouchane, Xavier Estivill, Khalid Fakhro, Hamdi Mbarek, Younes Mokrab, Jithesh V Puthen, Karsten Suhre, Zohreh Tatari
- Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
- Matthew R Smith, Howard I Scher, Shahneen Sandhu, Eleni Efstathiou, Primo N Lara, Evan Y Yu, Daniel J George, Kim N Chi, Fred Saad, Olof Ståhl, David Olmos, Daniel C Danila, Gary E Mason, Byron M Espina, Xin Zhao, Karen A Urtishak, Peter Francis, Angela Lopez-Gitlitz, Karim Fizazi, GALAHAD investigators, Francis Parnis, Anthony M. Joshua, Lisa G. Horvath, Christopher Steer, Gavin Marx, Shahneen Sandhu, Howard Gurney, Thomas Ferguson, Siska Van Bruwaene, Daisy Luyten, Peter Schatteman, Nicolaas Lumen, Luc Dirix, Jean-Charles Goeminne, Thierry Gil, Emmanuel Seront, Christof Vulsteke, Celio Kussumoto, Fabio A. Franke, Fabricio Augusto Martinelli de Oliveira, Andrea Juliana Pereira de Santana Gomes, Hélio Pinczowski, Daniel D’Almeida Preto, Luis Eduardo Zucca, Giuliano Santos Borges, Andre M. Murad, Fred Saad, Kim N. Chi, Yves Fradet, Neil E. Fleshner, Urban Emmenegger, Klaus Brasso, Karim Fizazi, Stephane Culine, Antoine Thiery-Vuillemin, Florence Joly, Aude Fléchon, Werner Hilgers, Jean-Christophe Eymard, Delphine Borchiellini, Philippe Barthélémy, Raanan Berger, Raya Leibowitz-Amit, Wilmosh Mermershtain, Keren Rouvinov, Avivit Peer, Svetlana Kovel, Avishay Sella, Martijn P. Lolkema, Alfonsus J.M. van den Eertwegh, Johannes Voortman, Maureen J. Aarts, Jourik A. Gietema, Choung-Soo Kim, Young-Deuk Choi, Byung-Ha Chung, Rustem A. Gafanov, Evgeniy Kopyltsov, Evgeny A. Usynin, Joan Carles, Begoña Mellado, José Pablo Maroto, Jesús García-Donás, Juan Francisco Rodríguez Moreno, Ignacio Durán, Begoña Pérez-Valderrama, Elena Castro, David Olmos, María José Méndez-Vidal, David Lorente Estellés, Regina Gironés Sarrió, José Muñoz-Langa, Urbano Anido Herranz, Javier Puente Vázquez, Enrique Castellanos, Martin Hellström, Anders Widmark, Ingela Franck Lissbrant, Åsa Jellvert, Cecilia Külich, René Blom, Olof Ståhl, Po-Hui Chiang, Chih-Hsiung Kang, Yen-Chuan Ou, Shian-Shiang Wang, Hsi-Chin Wu, Yu-Chuan Lu, Gerhardt Attard, Vincent Khoo, Amit Bahl, Prasad Kellati, Omi Parikh, Rajaguru Srinivasan, Jason F. Lester, John N. Staffurth, Heather H. Cheng, Eleni Efstathiou, Patrick G. Pilié, Daniel J. George, Lawrence I. Karsh, W. Kevin Kelly, Daniel C. Danila, Paul R. Sieber, Matthew R. Smith, Elisabeth I. Heath, Ulka N. Vaishampayan, Thomas W. Flaig, Hamid Emamekhoo, Jacek K. Pinski, Arash Rezazadeh Kalebasty, Joseph J. Maly, Helen Moon
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?